"Viral Plaque Assay" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Method for measuring viral infectivity and multiplication in CULTURED CELLS. Clear lysed areas or plaques develop as the VIRAL PARTICLES are released from the infected cells during incubation. With some VIRUSES, the cells are killed by a cytopathic effect; with others, the infected cells are not killed but can be detected by their hemadsorptive ability. Sometimes the plaque cells contain VIRAL ANTIGENS which can be measured by IMMUNOFLUORESCENCE.
| Descriptor ID |
D010948
|
| MeSH Number(s) |
E01.370.225.875.970.790 E05.200.875.970.790
|
| Concept/Terms |
Viral Plaque Assay- Viral Plaque Assay
- Assay, Viral Plaque
- Assays, Viral Plaque
- Plaque Assay, Viral
- Plaque Assays, Viral
- Viral Plaque Assays
Bacteriophage Plaque Assay- Bacteriophage Plaque Assay
- Assay, Bacteriophage Plaque
- Assays, Bacteriophage Plaque
- Bacteriophage Plaque Assays
- Plaque Assay, Bacteriophage
- Plaque Assays, Bacteriophage
|
Below are MeSH descriptors whose meaning is more general than "Viral Plaque Assay".
Below are MeSH descriptors whose meaning is more specific than "Viral Plaque Assay".
This graph shows the total number of publications written about "Viral Plaque Assay" by people in this website by year, and whether "Viral Plaque Assay" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2004 | 0 | 3 | 3 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2017 | 0 | 2 | 2 |
| 2018 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Viral Plaque Assay" by people in Profiles.
-
Zika Virus and the World Health Organization Criteria for Determining Recent Infection Using Plaque Reduction Neutralization Testing. Am J Trop Med Hyg. 2018 09; 99(3):780-782.
-
Characterization of recombinant yellow fever-dengue vaccine viruses with human monoclonal antibodies targeting key conformational epitopes. Vaccine. 2019 07 26; 37(32):4601-4609.
-
Safety and immunogenicity of the rVSV?G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. Lancet Infect Dis. 2017 08; 17(8):854-866.
-
Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial. Vaccine. 2017 03 23; 35(13):1675-1682.
-
Comparison of plaque- and enzyme-linked immunospot-based assays to measure the neutralizing activities of monoclonal antibodies specific to domain III of dengue virus envelope protein. Clin Vaccine Immunol. 2012 Jan; 19(1):73-8.
-
Evaluation of chimeric Japanese encephalitis and dengue viruses for use in diagnostic plaque reduction neutralization tests. Clin Vaccine Immunol. 2009 Jul; 16(7):1052-9.
-
Use of a surrogate chimeric virus to detect West Nile virus-neutralizing antibodies in avian and equine sera. Clin Vaccine Immunol. 2009 Jan; 16(1):134-5.
-
A single M protein mutation affects the acid inactivation threshold and growth kinetics of a chimeric flavivirus. Virology. 2007 Jun 05; 362(2):468-74.
-
Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese encephalitis (ChimeriVax)-JE) in non-human primates. Hum Vaccin. 2005 May-Jun; 1(3):106-11.
-
Differential ability of two simian virus 40 strains to induce malignancies in weanling hamsters. Virology. 2004 Dec 05; 330(1):168-77.